Brilinta Indications/Uses

BRILINTA 90 mg: BRILINTA 90 mg co-administered with ASA 75-100 mg is indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with acute coronary syndromes (ACS) [unstable angina, non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI)] including patients managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
BRILINTA 60 mg: BRILINTA 60 mg is indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing a thrombotic event and have at least 1 of the following risk factors: Age ≥65 years; Diabetes mellitus requiring medication; Documented history of a second prior presumed spontaneous MI (>1 year ago); Documented history of angiographic evidence of multivessel CAD (stenosis ≥50% in 2 major coronary artery territories [ie. left anterior descending, ramus intermedius, left circumflex, right coronary artery], involving the main vessel, a major branch, or a bypass graft); Chronic, non-end stage renal dysfunction (creatinine clearance calculated by Cockroft Gault equation <60 ml/min).